The U.S. Patent & Trademark Office’s patent trial board has ruled in favor of Becton Dickinson & Co. (NYSE:BDX) in a case involving a catheter-assembly patent held by One StockDuq Holdings.
The board found that 8 claims listed in One StockDuq’s patent ‘914 were unpatentable due to anticipation or obviousness.
In April 2013, Becton Dickinson filed for an inter partes review of patent ‘914, asserting that several of its claims were unpatentable. A trial was instituted in October of that year.
Earlier this month BD offered to pay $12.2 billion for CareFusion (NYSE:CFN).